Editas Medicine, Inc.
- EDIT
- NASDAQ
- Biotechnology
- Gene Editing (CRISPR)
- Clinical-Stage Biotech
$2.42
Today +2.98%Quote Oct 19, 2026, 08:00 PM UTC
−10.37%over the last month
Max drawdown −22.3%From 1-month high −17.1%3 months −16.3%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Editas Medicine
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
87
Founded
2013
Market value
$371.7M
Quote Oct 19
Floor
$2.36
2.5% below price
Resistance
$2.41
Price is above this level
Price vs analyst targets
26 analysts
Lowest target
$4.00Highest target
$6.00
$4.00Highest target
$6.00
- Price $2.42
- Average target $5.00
- Analysts' target range
The price is below even the lowest analyst target. Analysts' average target sits about 107% higher.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about EDITPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free